AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
Log in

NASDAQ:CELGCelgene News Headlines

$108.24
0.00 (0.00 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$108.24
Now: $108.24
$108.24
50-Day Range
$108.24
MA: $108.24
$108.24
52-Week Range
$58.59
Now: $108.24
$110.70
VolumeN/A
Average Volume6.77 million shs
Market Capitalization$77.04 billion
P/E Ratio14.22
Dividend YieldN/A
Beta1.41

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
Bristol-Myers Squibb: Growth And Valuation Trump Other Concerns - Seeking AlphaBristol-Myers Squibb: Growth And Valuation Trump Other Concerns - Seeking Alpha
seekingalpha.com - July 3 at 8:29 AM
Celgene Deal Starting to Pay Off Big for Bristol-Myers - Yahoo FinanceCelgene Deal Starting to Pay Off Big for Bristol-Myers - Yahoo Finance
finance.yahoo.com - July 2 at 8:55 AM
­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions - Benzinga­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions - Benzinga
www.benzinga.com - July 2 at 12:02 AM
Will There Be More Small Business Relief? Data Shows Its Sorely Needed - NasdaqWill There Be More Small Business Relief? Data Shows It's Sorely Needed - Nasdaq
www.nasdaq.com - June 27 at 6:41 PM
Better Buy: Amgen vs. Bristol Myers Squibb - Motley FoolBetter Buy: Amgen vs. Bristol Myers Squibb - Motley Fool
www.fool.com - June 27 at 1:40 PM
3 Top Pharma Stocks to Buy in a Recession - Motley Fool3 Top Pharma Stocks to Buy in a Recession - Motley Fool
www.fool.com - June 27 at 8:40 AM
15 of the Best Dividend Stocks to Buy for 202015 of the Best Dividend Stocks to Buy for 2020
finance.yahoo.com - June 25 at 8:59 AM
Bristol-Myers Squibb’s Cancer Drug Pipeline Could Bring Sales of $20 Billion - BarronsBristol-Myers Squibb’s Cancer Drug Pipeline Could Bring Sales of $20 Billion - Barron's
www.barrons.com - June 24 at 7:20 PM
3 Off-the-Cuff Second Stimulus Proposals Being Considered - Nasdaq3 Off-the-Cuff Second Stimulus Proposals Being Considered - Nasdaq
www.nasdaq.com - June 21 at 8:53 AM
Behcet Disease Drug Market Next Big Thing | Major Giants AbbVie, Celgene, Cell Medica, Coherus BioSciencesBehcet Disease Drug Market Next Big Thing | Major Giants AbbVie, Celgene, Cell Medica, Coherus BioSciences
www.marketwatch.com - June 20 at 8:53 AM
Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb - Business WireUbiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb - Business Wire
www.businesswire.com - June 17 at 1:02 PM
Celgene (NASDAQ:CELG) Earning Very Negative News Coverage, Report ShowsCelgene (NASDAQ:CELG) Earning Very Negative News Coverage, Report Shows
www.americanbankingnews.com - June 16 at 6:40 PM
Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property - Yahoo FinanceDyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property - Yahoo Finance
finance.yahoo.com - June 11 at 1:00 PM
Biohaven Pharma (BHVN) Names Bob Hugin to Board - StreetInsider.comBiohaven Pharma (BHVN) Names Bob Hugin to Board - StreetInsider.com
www.streetinsider.com - June 10 at 10:08 AM
Biohaven Appoints Bob Hugin to its Board of Directors - Yahoo FinanceBiohaven Appoints Bob Hugin to its Board of Directors - Yahoo Finance
finance.yahoo.com - June 10 at 10:08 AM
Bristol Myers Is Launching A New MS Drug — But Is BMY Stock A Buy?Bristol Myers Is Launching A New MS Drug — But Is BMY Stock A Buy?
finance.yahoo.com - June 10 at 10:08 AM
AstraZeneca And Gilead Sciences Merger Rumors - Something To Watch - Seeking AlphaAstraZeneca And Gilead Sciences Merger Rumors - Something To Watch - Seeking Alpha
seekingalpha.com - June 9 at 3:32 AM
AstraZeneca Made a Bid for Gilead, According to Reports - BarronsAstraZeneca Made a Bid for Gilead, According to Reports - Barron's
www.barrons.com - June 7 at 3:02 PM
3 Top Biotech Stocks to Buy in June - Motley Fool3 Top Biotech Stocks to Buy in June - Motley Fool
www.fool.com - June 6 at 5:25 PM
Jounce Therapeutics (JNCE) Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb - StreetInsider.comJounce Therapeutics (JNCE) Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb - StreetInsider.com
www.streetinsider.com - June 6 at 12:25 PM
Bristol-Myers (BMY) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo FinanceBristol-Myers (BMY) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
finance.yahoo.com - June 6 at 12:25 PM
Anti - Neoplastic Agents Market Size Estimated to Observe Significant Growth by 2025Anti - Neoplastic Agents Market Size Estimated to Observe Significant Growth by 2025
www.marketwatch.com - June 5 at 10:20 AM
Form 8-K Jounce Therapeutics, For: Jun 01 - StreetInsider.comForm 8-K Jounce Therapeutics, For: Jun 01 - StreetInsider.com
www.streetinsider.com - June 5 at 5:19 AM
Jounce regains rights to cancer candidate from Bristol Myers Squibb - Seeking AlphaJounce regains rights to cancer candidate from Bristol Myers Squibb - Seeking Alpha
seekingalpha.com - June 4 at 12:31 PM
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb - GlobeNewswireJounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb - GlobeNewswire
www.globenewswire.com - June 4 at 12:31 PM
Better Buy: Bristol Myers Squibb vs. Gilead Sciences - Motley FoolBetter Buy: Bristol Myers Squibb vs. Gilead Sciences - Motley Fool
www.fool.com - June 4 at 7:29 AM
Ependymoma Drug Market 2020 Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2025Ependymoma Drug Market 2020 Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2025
www.marketwatch.com - June 3 at 7:28 AM
Biond Biologics Appoints Jerome Zeldis, MD, Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update - GlobeNewswireBiond Biologics Appoints Jerome Zeldis, MD, Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update - GlobeNewswire
www.globenewswire.com - June 1 at 6:02 PM
Cancer Treatment Drugs Market 2020 Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2025Cancer Treatment Drugs Market 2020 Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2025
www.marketwatch.com - June 1 at 1:02 PM
Bristol-Myers Deserves Better Than a Single-Digit Multiple - Yahoo FinanceBristol-Myers Deserves Better Than a Single-Digit Multiple - Yahoo Finance
finance.yahoo.com - June 1 at 12:37 AM
Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report? - Yahoo FinanceWhy Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report? - Yahoo Finance
finance.yahoo.com - May 30 at 1:15 PM
The No. 1 Pharma Is Poised For Double-Digit Growth — Is BMY Stock A Buy?The No. 1 Pharma Is Poised For Double-Digit Growth — Is BMY Stock A Buy?
finance.yahoo.com - May 27 at 12:29 PM
Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?Is Amgen Stock A Buy As It Takes A Two-Pronged Approach To Coronavirus?
finance.yahoo.com - May 27 at 12:29 PM
Regulatory Deep Dive On The Celgene CVR - Seeking AlphaRegulatory Deep Dive On The Celgene CVR - Seeking Alpha
seekingalpha.com - May 22 at 8:02 PM
Regulatory Deep Dive On The Celgene CVRRegulatory Deep Dive On The Celgene CVR
seekingalpha.com - May 22 at 3:58 PM
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?” - Motley FoolFDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?” - Motley Fool
www.fool.com - May 22 at 3:02 PM
Could This Cancer Drug Developer’s Stock Make You Filthy Rich?Could This Cancer Drug Developer’s Stock Make You Filthy Rich?
www.fool.com - May 20 at 7:27 AM
Buy Bristol-Myers Squibb For 25% Gains? - ForbesBuy Bristol-Myers Squibb For 25% Gains? - Forbes
www.forbes.com - May 20 at 6:54 AM
45% of Workers Are Expecting Employment Changes. Heres How to Prepare. - Nasdaq45% of Workers Are Expecting Employment Changes. Here's How to Prepare. - Nasdaq
www.nasdaq.com - May 18 at 7:30 AM
3 Retail Earnings Reports to Watch Next Week - Nasdaq3 Retail Earnings Reports to Watch Next Week - Nasdaq
www.nasdaq.com - May 17 at 2:54 PM
The Oil Industry Has Been Quietly Cashing In on the CARES Act - NasdaqThe Oil Industry Has Been Quietly Cashing In on the CARES Act - Nasdaq
www.nasdaq.com - May 17 at 2:54 PM
Better Buy: Pfizer vs. Bristol Myers Squibb - Motley FoolBetter Buy: Pfizer vs. Bristol Myers Squibb - Motley Fool
www.fool.com - May 17 at 2:54 PM
How Much It’ll Cost To Get a Coronavirus VaccineHow Much It’ll Cost To Get a Coronavirus Vaccine
finance.yahoo.com - May 16 at 12:57 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT - Yahoo FinanceSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT - Yahoo Finance
finance.yahoo.com - May 15 at 8:18 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT - GlobeNewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT - GlobeNewswire
www.globenewswire.com - May 15 at 3:17 PM
BMY.RT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bristol-Myers Squibb Company and Encourages Investors to Contact the Firm - Yahoo FinanceBMY.RT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bristol-Myers Squibb Company and Encourages Investors to Contact the Firm - Yahoo Finance
finance.yahoo.com - May 14 at 1:06 PM
Is Bristol Myers Squibb Losing Its Edge As A Growth Stock? - Motley FoolIs Bristol Myers Squibb Losing Its Edge As A Growth Stock? - Motley Fool
www.fool.com - May 13 at 7:00 AM
Former Celgene Shareholders Contingent Value Rights Slip Further Away - Motley FoolFormer Celgene Shareholders' Contingent Value Rights Slip Further Away - Motley Fool
www.fool.com - May 8 at 4:26 PM
3 Reasons Bristol Myers Squibbs Revenue Skyrocketed in Q1 - The Motley Fool3 Reasons Bristol Myers Squibb's Revenue Skyrocketed in Q1 - The Motley Fool
www.fool.com - May 7 at 11:21 AM
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020 - GlobeNewswireCellectis Provides Business Update and Reports Financial Results for First Quarter 2020 - GlobeNewswire
www.globenewswire.com - May 7 at 6:18 AM
This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.